

## Erratum to: Abstracts of the 53rd Annual Meeting of the EASD, Lisbon 2017. Abstract 788: 'Pharmacokinetics and tolerability of oral semaglutide in subjects with renal impairment'

T. W. Anderson<sup>1</sup> · C. Granhall<sup>1</sup> · Á. Réthy<sup>2</sup> · F. L. Søndergaard<sup>1</sup> · M. Thomsen<sup>1</sup>

Published online: 23 August 2017  
© Springer-Verlag GmbH Germany 2017

### Erratum to: Diabetologia

<http://dx.doi.org/10.1007/s00125-017-4350-z>

T.W. Anderson<sup>1</sup>, C. Granhall<sup>1</sup>, Á. Réthy<sup>2</sup>, F.L. Søndergaard<sup>1</sup>,  
M. Thomsen<sup>1</sup>

<sup>1</sup>Novo Nordisk, Søborg, Denmark, <sup>2</sup>Péterfy Sándor utcai  
Kórház, Budapest, Hungary.

The original version of this abstract unfortunately contained a mistake. Instead of a table a figure was erroneously published. The correct table is given below.

**Semaglutide exposure in subjects with renal impairment versus subjects with normal renal function**

	AUC <sub>0-24h, Day 10</sub> Ratio [90% CI]	C <sub>max, Day 10</sub> Ratio [90% CI]
Mild vs. Normal	1.37 [0.91;2.06]	1.39 [0.93;2.06]
Moderate vs. Normal	1.13 [0.69;1.84]	1.20 [0.75;1.93]
Severe vs. Normal	0.61 [0.42;0.88]	0.61 [0.42;0.87]
ESRD vs. Normal	1.02 [0.59;1.79]	1.06 [0.61;1.84]

AUC<sub>0-24h, Day 10</sub>: Area under the semaglutide plasma concentration-time curve from 0 to 24 hours after the 10<sup>th</sup> daily dose

C<sub>max, Day 10</sub>: Maximum semaglutide plasma concentration after the 10<sup>th</sup> daily dose

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-017-4350-z>

✉ T. W. Anderson

<sup>1</sup> Novo Nordisk, Søborg, Denmark

<sup>2</sup> Péterfy Sándor utcai Kórház, Budapest, Hungary